osteopetrosis [ Albers-Schönberg disease | marble bones | ivory bones ]

infectious disease [ bacterial disease | cholera | communicable disease | contagious disease | leprosy | malaria | parasitic disease | sleeping sickness | trypanosomiasis | tuberculosis | viral disease | viral diseases | yellow fever ]

illness [ disease | human disease(GEMET) ]

blue disease | blue ear disease | blue-ear disease of pigs | mysterious pig disease | mysterious swine disease | mystery pig disease | new pig disease | porcine epidemical abortion | porcine reproductive and respiratory syndrome | purple ears disease | MSD [Abbr.] | PRRS [Abbr.]

disease of the nervous system [ Alzheimer's disease | CJD | Creutzfeldt-Jakob disease | degenerative disease of the nervous system | multiple sclerosis | neurological disease | neuropathy | transmissible spongiform encephalopathy | TSE ]

Kashin-Beck disease [ KBD | Kashin-Bek disease | osteoarthritis deformans endemica | big bone disease ]

metabolic bone disease [ developmental orthopedic disease ]

Paget's disease of bone | Paget disease of bone | Paget's disease | Paget disease | osteitis deformans

alveolar bone

Statistics Canada's recent survey of 5,300 Canadians showed nearly two-thirds had insufficient blood levels to protect against serious disease and 1 in 10, or 3, million were so low as to be at risk of bone disease.

Specific activities shall include: understanding the determinants of health (including nutrition, physical activity and gender, and environmental, socio-economic, occupational and climate-related factors); improving health promotion and disease prevention; understanding disease and improving diagnosis and prognosis; developing effective prevention and screening programmes and improving the assessment of disease susceptibility; improving the surveillance of infectious diseases and preparedness for combating epidemics and emerging diseases; developing new and better preventive and therapeutic vaccines and drugs; using in-silico medicine for improving disease management and prediction; developing regenerative medicine and adapted treatm ...[+++]ents, and treating disease, including palliative medicine; transferring knowledge to clinical practice and scalable innovation actions; improving health information and better collection and use of health cohort and administrative data; standardised data analysis and techniques; active ageing, and independent and assisted living; individual awareness and empowerment for self-management of health; promotion of integrated care, including psychosocial aspects; improving scientific tools and methods to support policy making and regulatory needs; optimising the efficiency and effectiveness of healthcare provision; and reducing health disparities and inequalities by evidence-based decision making and dissemination of best practice and by innovative technologies and approaches.

Medical isotope production at NRU has supported the health and well-being of Canadian citizens for both diagnosis and treatment of heart disease, bone disease, and cancer.

Maintain the EU’s coordinative role in the development of the EU policy on rare diseases and to support Member States in their activities on the national level. Continue to support the development of high quality National Rare Diseases Plans/Strategies in the European Union. Provide continued support for the International Rare Disease Research Consortium and initiatives developed under its umbrella. Continue to ensure proper codification of rare diseases. Work further to decrease inequalities between patients with rare diseases and patients suffering from more common disorders and to support initiatives promoting equal access to diagnosi ...[+++]s and treatment. Continue to promote patients empowerment in all aspects of rare diseases policy development Continue activities increasing public awareness about rare diseases and EU activity in this field Make use of the Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare to bring together European Reference Networks on rare diseases. Support the development of the tools facilitating cooperation and interoperability of the European Reference Networks for rare diseases. Stimulate development and use of eHealth solutions in the area of rare diseases. Implement and continue support for the European Platform on rare diseases registration. Continue playing a global role in the rare diseases initiative and collaborating with important international stakeholders.